Fundz

Quralis Closes $88 Million Series B Financing To Advance Precision Medicines For Neurodegenerative Diseases

PRIVATEMar 09, 2023

Amount Raised

$88 Million

Round Type

Series B

CambridgeBiotechnologyHealthcareHealth CareTherapeutics

Investors

Dolby Family VenturesSanford BiosciencesMission Bay CapitalDementia Discovery FundInkef CapitalMission Bio CapitalLs Polaris Innovation FundAls Investment FundLsp Dementia FundAmgen VenturesMp Healthcare Venture ManagementMitsui Global InvestmentEQT Life SciencesDroia VenturesSanofi Ventures

Description

QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets, today announced it has closed an oversubscribed $88 million Series B financing, bringing the total funds raised to $143.5 million. The financing was led by EQT Life Sciences, investing from the LSP Dementia Fund, Sanofi Ventures, and Droia Ventures, with participation from the ALS Investment Fund and existing investors LS Polaris Innovation Fund, Mission BioCapital, INKEF Capital, Dementia Discovery Fund, Amgen Ventures, MP Healthcare Venture Management, Mitsui Global Investment, Dolby Family Ventures, Mission Bay Capital, and Sanford Biosciences.

Company Information

Company

QurAlis

Location

Cambridge, Massachusetts, United States

About

QurAlis is a pioneering neuroscience company dedicated to developing precision medicines that target the root causes of neurodegenerative and neurological diseases. With leading expertise in amyotrophic lateral sclerosis (ALS), the company is committed to translating scientific breakthroughs into transformative therapies. Guided by collaboration, scientific rigor, and compassion, QurAlis is advancing a robust pipeline of disease-modifying treatments driven by genetics and clinical biomarkers to improve the lives of patients with severe neurological conditions.

Fundz sees it the moment QurAlis raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsDaniel E., Executive Officer hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for QurAlis's next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

QurAlis raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.